<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03930602</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-088</org_study_id>
    <nct_id>NCT03930602</nct_id>
  </id_info>
  <brief_title>Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165</brief_title>
  <official_title>An Open-label, Single-sequence Study to Investigate the Effects of Cytochrome P450 1A2 Inhibition on the Pharmacokinetics of BMS-986165 in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetic characteristics of BMS-986165 after a single-dose
      administration alone vs. in combination with fluvoxamine (CYP1A2 inhibitor)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">May 27, 2019</completion_date>
  <primary_completion_date type="Actual">May 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-986165</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-T) of BMS-986165</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(INF) of BMS-986165</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fluvoxamine steady-state plasma concentrations</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Adverse events (AEs)</measure>
    <time_frame>From screening up to end of drug treatment (Day 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Serious Adverse events (SAEs) and Death</measure>
    <time_frame>From screening up to end of drug treatment (Day 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Adverse events (AEs) leading to discontinutation</measure>
    <time_frame>From screening up to end of drug treatment (Day 13)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinical significant laboratory abnormalities vital sign measurements and ECGs</measure>
    <time_frame>From screening up to end of drug treatment (Day 13)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BMS-986165+Fluvoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986165 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluvoxamine only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Participants will receive BMS-986165.</description>
    <arm_group_label>BMS-986165 only</arm_group_label>
    <arm_group_label>BMS-986165+Fluvoxamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>Participants will receive fluvoxamine.</description>
    <arm_group_label>BMS-986165+Fluvoxamine</arm_group_label>
    <arm_group_label>Fluvoxamine only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participant, as determined by no clinically significant deviation from normal
             in medical history, physical examination, electrocardiograms (ECGs), and clinical
             laboratory determinations in the opinion of the investigator.

          -  Body mass index of 18 to 32 kilograms per square meter (kg/m2), inclusive, and body
             weight â‰¥ 50 kg, at screening.

          -  Normal renal function at screening as evidenced by an estimated glomerular filtration
             rate (GFR) &gt; 80 milliliter/minute/1.732 meter square calculated with the Chronic
             Kidney Disease Epidemiology Collaboration formula.

        Exclusion Criteria:

          -  Any significant acute or chronic medical condition that presents a potential risk to
             the participant and/or may compromise the objectives of the study,

          -  Any major surgery within 4 weeks of study drug administration

          -  Participants who currently smoke, as well as those who have stopped smoking less than
             6 months prior to dosing on Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvoxamine</mesh_term>
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

